We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Losartan treating podocyte injury induced by Ang II via downregulation of TRPC6 in podocytes.
- Authors
Chi-Xianggeng; Hu-Bo; Yu, S. Y.; Yin-Lianghong; Meng-Yu; Wang-Boxun; Yang-Jinsheng; Lin-Jiahui; Huang-Dexu; Chen-lanlan
- Abstract
<bold>Objective: </bold>In this study, we investigated the molecule mechanisms of podocyte injury and proteinuria and the protective effects of losartan.<bold>Methods: </bold>This study set up three groups: a control group; an Ang II group (Ang II 10(-6) mol/l, Sigma); and a losartan group (losartan 10(-6) mol/l, Sigma). We used RT-PCR assay to detect TRPC6 mRNA expression, and Western blot to detect TRPC6 protein expression.<bold>Results: </bold>TRPC6 overexpression was the basic change of podocyte injury and proteinuria occurrence. Losartan can treat podocyte injury and proteinuria induced by Ang II via downregulation of TRPC6 in podocytes.<bold>Conclusion: </bold>These findings maybe provide an ideal drug target for the diagnosis and treatment of acquired glomerular diseases.
- Subjects
RNA metabolism; ANIMAL experimentation; BIOCHEMISTRY; CARRIER proteins; EPITHELIAL cells; PHENOMENOLOGY; MICE; RNA; WESTERN immunoblotting; ANGIOTENSIN II; LOSARTAN; PHARMACODYNAMICS; THERAPEUTICS
- Publication
Journal of the Renin-Angiotensin-Aldosterone System, 2015, Vol 16, Issue 4, p1118
- ISSN
1470-3203
- Publication type
journal article
- DOI
10.1177/1470320315573682